https://www.benzinga.com/general/biotech/24/12/42505309/exclusive-soligenix-starts-confirmatory-late-stage-trial-for-hybryte-for-type-of-blood-cancer
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer -...
Dec 16, 2024 - Soligenix opens enrollment for the Phase 3 FLASH2 study of HyBryte in early-stage CTCL, aiming to confirm extended treatment efficacy over 18 weeks.
https://markets.businessinsider.com/news/stocks/soligenix-completes-enrollment-of-patients-for-phase-3-study-evaluating-hybryte-1035578816
Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte | Markets Insider
Soligenix (SNGX) announced that it has completed the planned enrollment of 50 patients necessary for the interim analysis in its 80 patient conf...